Mineralys Therapeutics, Inc. (MLYS)
Nasdaq: MLYS · Pharmaceutical Preparations · Radnor, PA · filing with the SEC since 2022
Who runs Mineralys Therapeutics, Inc.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Congleton Jon
Chief Executive Officer. First filing Feb 2023, latest Oct 2, 2026, 19 filings in all.
Officers reporting now
5
of 18 people with a filing in the last fifteen months
Directors reporting now
13
21 people on the record since 2023
Officerssales are open-market, Oct 20, 2025 to Oct 20, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Congleton Jon | Chief Executive Officer | Feb 2023 | Oct 2, 2026 | 16 · $16.2M |
| Warren Eric | Chief Commercial Officer | Mar 2026 | Sep 22, 2026 | 4 · $3.3M |
| Ferguson James J. III | Chief Medical Officer | Aug 2026 | Aug 12, 2026 | none |
| Rodman David Malcom | Chief Medical Officer | Feb 2023 | Aug 12, 2026 | 38 · $14.0M |
| Levy Adam Scott | CFO and Secretary | Feb 2023 | Feb 20, 2026 | 10 · $5.7M |
Directorssales are open-market, Oct 20, 2025 to Oct 20, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Coats Lonnel | director | Oct 2026 | Oct 20, 2026 | none |
| Peterson Kristine | director | Oct 2026 | Oct 20, 2026 | none |
| Slingsby Brian Taylor | director | Feb 2023 | Sep 24, 2026 | 1 · $3.0M |
| Karydas Daphne | director | Sep 2023 | Sep 17, 2026 | 5 · $900,000 |
| Kolchinsky Peter | director | Feb 2023 | Mar 31, 2026 | none |
| Ra Capital Healthcare Fund LP | director | Feb 2023 | Mar 31, 2026 | none |
| Ra Capital Management, L.P. | director | Feb 2023 | Mar 31, 2026 | none |
| Ra Capital Nexus Fund III, L.P. | director | Feb 2023 | Mar 31, 2026 | none |
| Shah Rajeev M. | director | Feb 2023 | Mar 31, 2026 | none |
| Akkaraju Srinivas | director | Feb 2023 | Feb 20, 2026 | none |
| Dirocco Derek | director | Feb 2023 | Feb 20, 2026 | none |
| Gold Alexander M | director | Jun 2024 | Feb 20, 2026 | 5 · $1.6M |
| Sblendorio Glenn | director | Sep 2023 | Feb 20, 2026 | none |
Owners of more than 10% of a classsales are open-market, Oct 20, 2025 to Oct 20, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Catalys Pacific Fund, LP | 10% owner | Feb 2023 | Nov 21, 2025 | 1 · $43.4M |
Earlier names on the record6, newest filing first
Samsara Biocapital Gp, LLC · 10% owner · last filing Mar 2025Samsara Biocapital, L.P. · 10% owner · last filing Mar 2025Litzka Olivier · director · last filing May 2024Takahashi Takeshi · director · last filing Jul 2023Hbm Healthcare Investments (Cayman) Ltd. · 10% owner · last filing Feb 2023Asam Alexander · director · last filing Feb 2023
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.